Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Dec 28, 2009; 15(48): 6102-6110
Published online Dec 28, 2009. doi: 10.3748/wjg.15.6102
Published online Dec 28, 2009. doi: 10.3748/wjg.15.6102
Authors | Country | Form | Trial design | Case No. (Az/con) | Patients | Diagnostic methods | Azithromycin regimen | % Eradication (n) | % Adverse effects (n) | Triple therapy | Days of antibiotics | % Eradication (n) | % Adverse effects (n) | Q |
Lu et al[24], 2007 | China | JA | Single centre RCT | 85 (43/42) | H pylori positive | RUT/ | O (20 mg bid) | ITT 84 (36/43) | 26 (11/43) | O (20 mg bid) | 7 | ITT 69 (29/42) | 19 (8/42) | 3 |
Chronic active gastritis | RUT (30 d later) | Lev (200 mg bid) | PP 90 (36/40) | A (1 g bid) | PP 72.5 (29/40) | |||||||||
Az (500 mg o.d.) | C (500 mg bid) | |||||||||||||
Kang et al[25], 2006 | Korea | JA | Single centre RCT | 78 (17/61) | H pylori positive | Histology + RUT or UBT/ | O (20 mg bid) | ITT 70.6 (12/17) | 11.8 (2/17) | O (20 mg bid) | 7 | ITT 80.3 (49/61) | 41.0 (25/61) | 3 |
Adults | Histology + RUT | Lev (500 mg o.d.) | PP 70.6 (12/17) | A (1 g bid) | PP 80.3 (49/61) | |||||||||
or UBT (8 wk later) | Az (500 mg o.d.) | C (500 mg bid) | ||||||||||||
Iacopini et al[26], 2005 | Italy | JA | Single centre RCT | 164 (83/81) | H pylori positive | Histology + UBT/ | E (20 mg o.d.) | ITT 65 (54/83) | 12 (9/77) | E (20 mg bid) | 7 | ITT 65 (53/81) | 30 (22/70) | 4 |
Peptic ulcer and | UBT + HpSA | Lev (500 mg o.d.) | PP 70 (54/77) | A (1 g bid) | PP 76 (53/70) | |||||||||
GERD adults | (8 wk later) | Az (500 mg o.d.) | C (500 mg bid) | |||||||||||
Zhao et al[27], 2005 | China | JA | Single centre RCT | 98 (49/49) | H pylori positive | Histology + RUT/ | O (20 mg bid) | ITT 73.5 (36/49) | / | O (20 mg bid) | 7 | ITT 30.6 (15/49) | / | 3 |
Active duodenal ulcer | RUT + Histology | A (1 g bid) | PP 76.6 (36/47) | A (1 g bid) | PP 31.3 (15/48) | |||||||||
(4 wk later) | Az (1 g o.d.) 3 d | M (500 mg bid) | ||||||||||||
Chen et al[28], 2004 | China | JA | Single centre RCT | 100 (55/45) | H pylori positive | Histology + UBT/ | O (40 mg o.d.) | ITT 92.7 (51/55) | 5 (3/55) | O (40 mg o.d.) | 7 | ITT 93.3 (42/45) | 17.8 (8/45) | 2 |
Active duodenal ulcer | UBT (6 wk later) | A (1 g bid) | PP 92.7 (51/55) | A (1 g bid) | PP 93.3 (42/45) | |||||||||
Az (500 mg o.d.) 3 d | C (500 mg bid) | |||||||||||||
Chen et al[29], 2002 | China | JA | Single centre RCT | 47 (24/23) | H pylori positive | Histology + RUT/ | L (30 mg o.d.) | ITT 92 (22/24) | 4 (1/24) | O (20 mg bid) | 7 | ITT 91 (21/23) | 9 (2/23) | 3 |
Chronic gastritis adults | UBT (4 wk later) | M (400 mg bid) 3 d | PP 92 (22/24) | M (400 mg bid) | PP 91 (21/23) | |||||||||
Az (500 mg o.d.) 3 d | C (500 mg bid) | |||||||||||||
Ivashkin et al[30], 2002 | Russia | JA | Multicenter RCT | 100 (50/50) | H pylori positive | Histology + RUT/ | O (20 mg bid) | ITT 72 (36/50) | / | O (20 mg bid) | 7 | ITT 30 (15/50) | / | 4 |
Active duodenal | Histology + RUT (8 wk later) | A (1 g bid) | PP 75 (36/48) | A (1 g bid) | PP 31 (15/49) | |||||||||
Ulcer adults | Az (1 g o.d.) 3 d | M (500 mg bid) | ||||||||||||
Laurent et al[31], 2001 | France | JA | Multicenter RCT | 247 (64/78/70) | H pylori positive | Histology + RUT/ | O (20 mg bid) | ITT 37.5 (24/64) | 56.9 (33/58) | O (20 mg bid) | 7 | ITT 71.8/61.4 (56/78) (43/70) | 57.7/66.1 | 4 |
Non-ulcer dyspepsia | UBT (4-6 wk later) | A (1 g bid) | PP 41.4 (24/58) | C (500 mg bid)/C (250 mg bid) | PP 78.9/69.4 (56/71) (43/62) | (41/71) (41/62) | ||||||||
Az (500 mg o.d.) day 1 + (250 mg o.d.) days 2-5 | A (1 g bid)/M (500 mg bid) | |||||||||||||
Vcev et al[32], 2000 | Croatia | JA | Single centre RCT | 110 (55/55) | H pylori positive | Histology + RUT/ | P (40 mg bid) | ITT 71 (39/55) | 14 (7/50) | P (40 mg bid) | 7 | ITT 78 (43/55) | 17 (9/53) | 3 |
Active duodenal ulcer | Histology + RUT | A (1 g bid) | PP 78 (39/50) | A (1 g bid) | PP 81 (43/53) | |||||||||
(8 wk later) | Az (500 mg o.d.) 6 d | C (500 mg bid) | ||||||||||||
Laine et al[33], 1999 | USA | JA | Single centre RCT | 120 (40/40/40) | H pylori positive | Histology or serology + UBT/ | O (80 mg o.d.) | ITT 65 (26/40) | 3 (1/38) | O (80 mg o.d.) | 10 | ITT 35/78 (14/40) (31/40) | 8/15 (3/37) (5/33) | 3 |
Symptomatic and | UBT (6 wk later) | M (750 mg o.d.) | PP 66 (25/38) | M (750 mg o.d.) | PP 35/79 (13/37) (26/33) | |||||||||
Asymptomatic adults | Az (500 mg o.d.) 7 d | A (1.5 g o.d.)/C (1 g o.d.) | ||||||||||||
Trevisani et al[34], 1998 | Italy | JA | Single centre RCT | 160 (80/80) | H pylori positive | RUT + Histology/ | L (30 mg bid) days 1-4 | ITT 73.3 (59/80) | 1.3 (1/73) | O (20 mg o.d.) | 7 | ITT 81.2 (65/80) | 2.6 (2/76) | 4 |
Symptomatic adults | RUT + Histology (4 wk later) | T (2000 mg o.d.) day 3 | PP 80.8 (59/73) | C (250 mg bid) | PP 85.5 (65/76) | |||||||||
Az (500 mg o.d.) days 2-4 | T (500 mg bid) | |||||||||||||
Caselli et al[35], 1997 | Italy | JA | Multicenter RCT | 120 (60/60) | H pylori positive | Histology + RUT/ | L (30 mg o.d.) | ITT 93.3 (56/60) | / | O (20 mg o.d.) | 7 | ITT 86.7 (52/60) | / | 3 |
Gastritis with or | Histology (7-8 wk later) | M (250 mg bid) 3 d | PP 93.3 (56/60) | C (250 mg bid) | PP 91.2 (52/57) | |||||||||
without peptic ulcer | Az (500 mg o.d.) 3 d | T (500 mg bid) | ||||||||||||
Leri et al[36], 1997 | Italy | Ab | Single centre RCT | 123 (41/41/41) | H pylori positive | Histology + RUT | O (20 mg bid) | ITT 68 (28/41) | / | O (20 mg bid) | 14 | ITT 80/97 (33/41) (40/41) | / | 2 |
M (500 mg bid) 10 d | M (500 mg bid) 10 d | |||||||||||||
Az (500 mg o.d.) 6 d | A (1 g bid) /C (500 mg t.d.) | |||||||||||||
Cammarota et al[37], 1996 | Italy | JA | Single centre RCT | 70 (35/35) | H pylori positive | Histology + RUT/ | L (30 mg o.d.) | ITT 57 (20/35) | 18 (6/33) | L (30 mg o.d.) | 7 | ITT 80 (28/35) | 26 (9/34) | 3 |
Symptomatic adults | Histology + RUT (8 wk later) | A (1 g bid) | PP 61 (20/33) | A (1 g bid) | PP 82 (28/34) | |||||||||
Az (500 mg o.d.) 3 d | C (250 mg bid) |
-
Citation: Dong J, Yu XF, Zou J. Azithromycin-containing
versus standard triple therapy forHelicobacter pylori eradication: A meta-analysis. World J Gastroenterol 2009; 15(48): 6102-6110 - URL: https://www.wjgnet.com/1007-9327/full/v15/i48/6102.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.6102